Study of IPM514 for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, IPM514, in people with advanced esophageal squamous cell carcinoma whose cancer has worsened after standard treatments like immunotherapy with PD-1/PD-L1 inhibitors and platinum chemotherapy. It aims to see if IPM514 can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a specific type of esophageal cancer called squamous cell carcinoma, confirmed by a biopsy.
- You have already tried at least one immunotherapy (like a PD-1/PD-L1 drug) and a platinum-based chemotherapy, but your cancer continued to grow during or after those treatments.
- You have a certain blood type marker called HLA-A*02:01 or HLA-A*11:01 (your doctor can test this).
- You are healthy enough to be up and about, with good organ function (heart, kidneys, liver, blood counts).
- You can have a measurable tumor on a CT scan (not just in an area that was previously treated with radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a precision medicine approach for people with advanced esophageal cancer that has stopped responding to immunotherapy. The goal is to find better treatments based on each person's tumor biology.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.